Profile data is unavailable for this security.
About the company
Shanghai Shyndec Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company is mainly engaged in the research and development, production and sales of pharmaceutical intermediates and active pharmaceutical ingredients as well as drug preparations. The Company's products cover the therapeutic areas of systemic anti-infective, cardiovascular, anti-tumor and immunomodulators, central nervous system, hormones, urogenital system, digestive tract and metabolism, respiratory system and other fields. The Company is also engaged in animal vaccines, big health and other businesses, providing medical beauty products and skin care products. The Company distributes its products within the domestic market and to overseas markets.
- Revenue in CNY (TTM)9.26bn
- Net income in CNY930.27m
- Incorporated1996
- Employees11.47k
- LocationShanghai Shyndec Pharmaceutical Co LtdNo. 378 Jianlu Road, Pudong New AreaSHANGHAI 200137ChinaCHN
- Phone+86 2 152372865
- Fax+86 2 158480136
- Websitehttps://www.shyndec.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tibet Rhodiola Pharmaceutical Holding Co | 2.72bn | 981.20m | 13.80bn | 596.00 | 14.07 | 3.89 | -- | 5.07 | 3.04 | 3.04 | 8.44 | 11.02 | 0.5188 | 1.38 | 6.52 | 4,564,666.00 | 18.84 | 14.99 | 25.61 | 19.30 | 92.08 | 92.11 | 36.31 | 23.95 | 2.89 | -- | 0.1971 | 52.89 | -10.45 | 17.45 | 31.26 | 27.47 | -5.16 | 27.43 |
| Shanghai Shyndec Pharmaceutical Co Ltd | 9.26bn | 930.27m | 14.48bn | 11.47k | 15.57 | 1.06 | -- | 1.56 | 0.6936 | 0.6936 | 6.91 | 10.17 | 0.4703 | 2.95 | 7.65 | 807,583.30 | 5.41 | 5.14 | 7.83 | 8.21 | 33.20 | 40.86 | 11.50 | 7.82 | 2.62 | -- | 0.003 | 20.02 | -9.38 | -2.16 | 56.62 | 10.55 | -11.46 | 24.57 |
| Shanghai Haoyuan Chemexpress Co Ltd | 2.71bn | 294.90m | 15.25bn | 3.58k | 51.52 | 4.90 | -- | 5.63 | 1.40 | 1.40 | 12.85 | 14.67 | 0.504 | 1.10 | 3.98 | 757,880.40 | 5.37 | 5.94 | 7.32 | 7.80 | 48.93 | 45.09 | 10.66 | 11.74 | 1.46 | 7.54 | 0.4102 | 16.95 | 20.75 | 40.89 | 58.17 | 22.38 | 71.42 | -- |
| Zhejiang Medicine Co Ltd | 8.96bn | 1.24bn | 15.52bn | 5.82k | 12.48 | 1.40 | -- | 1.73 | 1.29 | 1.29 | 9.31 | 11.50 | 0.6499 | 2.76 | 5.65 | 1,540,449.00 | 8.19 | 5.31 | 10.15 | 6.93 | 39.47 | 36.97 | 12.60 | 7.68 | 2.01 | -- | 0.0784 | 30.91 | 20.29 | 5.88 | 170.11 | 27.62 | 3.74 | -18.03 |
| Holder | Shares | % Held |
|---|---|---|
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 6.34m | 0.47% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 5.43m | 0.41% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 4.77m | 0.36% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 3.84m | 0.29% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 2.54m | 0.19% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 2.11m | 0.16% |
| Guolian Fund Management Co. Ltd.as of 30 Jun 2025 | 2.11m | 0.16% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 1.38m | 0.10% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 1.35m | 0.10% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2025 | 1.31m | 0.10% |
